GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shionogi & Co Ltd (TSE:4507) » Definitions » Debt-to-Equity

Shionogi (TSE:4507) Debt-to-Equity : 0.01 (As of Sep. 2024)


View and export this data going back to 1949. Start your Free Trial

What is Shionogi Debt-to-Equity?

Shionogi's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was 円3,289 Mil. Shionogi's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was 円8,364 Mil. Shionogi's Total Stockholders Equity for the quarter that ended in Sep. 2024 was 円1,292,792 Mil. Shionogi's debt to equity for the quarter that ended in Sep. 2024 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Shionogi's Debt-to-Equity or its related term are showing as below:

TSE:4507' s Debt-to-Equity Range Over the Past 10 Years
Min: 0   Med: 0.01   Max: 0.06
Current: 0.01

During the past 13 years, the highest Debt-to-Equity Ratio of Shionogi was 0.06. The lowest was 0.00. And the median was 0.01.

TSE:4507's Debt-to-Equity is ranked better than
99.88% of 826 companies
in the Drug Manufacturers industry
Industry Median: 0.27 vs TSE:4507: 0.01

Shionogi Debt-to-Equity Historical Data

The historical data trend for Shionogi's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shionogi Debt-to-Equity Chart

Shionogi Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01

Shionogi Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 N/A 0.01

Competitive Comparison of Shionogi's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Shionogi's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shionogi's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shionogi's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Shionogi's Debt-to-Equity falls into.



Shionogi Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Shionogi's Debt to Equity Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Shionogi's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shionogi  (TSE:4507) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Shionogi Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Shionogi's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Shionogi Business Description

Traded in Other Exchanges
Address
1-8, Doshomachi 3-chome, Chuo-ku, Osaka, JPN, 541-0045
Shionogi & Co Ltd is a specialty and generic drug manufacturing company. The company focuses on the manufacturing and distribution of pharmaceuticals, diagnostic reagents, and medical devices. Shionogi engages in manufacturing, formulation, packaging, and analysis as part of its commercialization research that spans late stage drug discovery through commercial production. The company's research and development strategy utilizes partnership and licensing opportunities with academic constituents and venture companies.

Shionogi Headlines

No Headlines